Menu
Menu
📍 National Institutes of Health (NIH), Kuala Lumpur, Malaysia | ⏱️ 2-hour session | 8 October 2026
An exclusive educational session for government laboratory specialists, bioinformaticians, and pathologists
About This Session
As genomic testing volumes continue to rise across public healthcare systems, laboratories are under increasing pressure to deliver faster, more consistent, and more clinically actionable results.
SOPHiA GENETICS, in partnership with Science Vision, invites government stakeholders at the forefront of genomic diagnostics in Malaysia to a dedicated educational session, offering a substantive discussion of the analytical and interpretive challenges facing genomic laboratories today, and how AI-powered platforms such as SOPHiA DDM™ are helping address them.
Participants will gain practical insight into modern genomic workflows, observe the platform in a live demonstration, and have the opportunity to contribute their own laboratory's challenges to the discussion.
Why Attend
Agenda
| Agenda |
|---|
| Welcome & Stakeholder Introductions |
| How SOPHiA DDM™ Tackles Real-World Genomic Challenges |
| Live Platform Demo — See SOPHiA DDM™ in action, from sample to report |
| User Experience Sharing |
| Open Discussion & Q&A |
Who Should Attend
Government laboratory specialists, bioinformaticians, pathologists, and public healthcare stakeholders involved in genomic testing and analysis.
Join us at the 2026 ASHG Annual Meeting in Montreal to explore how SOPHiA DDM™ supports genomic analysis and interpretation across rare and inherited disorders, including hereditary cancer, and pharmacogenomics.​
Visit us at Booth #517 to connect with our genomics experts, experience SOPHiA DDM™ firsthand and discover how a data driven approach can help laboratories streamline complex genomic workflows and turn data into meaningful insights.​
More ways to connect with us at ASHG​
Join us at our CoLab​
Hear about Trillium Health Partners’ approach to PMS2/PMS2CL disambiguation and see the latest data for our enhanced exome solutions.​
Friday, October 23 | 10.15-10.45 | CoLab Theatre 2​
Explore our poster presentation​
Comprehensive detection of SNVs / Indels, CNVs and complex gene conversions across germline applications using an enhanced exome approach​
Authors: Tamara Maas, Yuanlong Liu, Bita Khalili, Dmitri Ivanov, Alfredo Mari, Jian Yu, Rieke Kempfer, Zhenyu Xu​
Wednesday, October 21, 2:30-4:30 EDT​
Discover new data and insights from our latest work.​
Plan your ASHG visit​
Whether you're working on rare disorders, hereditary cancer, or pharmacogenomics, we'd love to connect and learn more about the challenges your laboratory is working to solve.​
Meeting slots at ASHG fill quickly. Book time with our team before you arrive in Montreal.
See you there. 🧬​
Join SOPHiA GENETICS at SFMPP 2026 in Paris, France! Come meet our team of experts at Booth #16. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions.
Stay tuned for information and session updates!
SOPHiA GENETICS is proud to join the 37th CBGM in SĂŁo LuĂs, MaranhĂŁo (Sept 2–5, 2026), celebrating 40 years of SBGM and the future of precision medicine in Brazil. Meet us at Booth #20 to discover the latest innovations of the New Generation SOPHiA DDM™ Platform, with a special focus on Exome advancements.
Join our BioPharma team to discover how AI-powered technology and diagnostics are helping advance precision oncology.
We are excited to join the 26th ACGH Congress — Asociación Colombiana de Genética Humana, taking place August 13–15 in Pereira, Colombia. Join us and meet our LATAM team to learn how SOPHiA DDM™ helps clinical genetics laboratories across the region implement optimized, technology-agnostic genomic testing — from exome design to actionable diagnosis.
The SOPHiA GENETICS team is looking forward to seeing you at our sponsored academic breakfast talk.
Academic Breakfast Talk on Friday, August 14th, from 8:00 to 9:00 am — Salón 1, Genética Médica.
"From Design to Diagnosis: Implementation of Optimized Exomes in Clinical Practice"
Luna RodrĂguez, MSc., Subject Matter Expert, SOPHiA GENETICS
Dr. Coztli Ocelotl Azotla, Geneticist, Genos MĂ©dica
In this talk, we will explore how optimized exome design is reshaping clinical genetics workflows across Latin America, bridging the gap between test design and real-world diagnostic impact.
Come find us at booth #19 for expert discussions and collaborative opportunities.
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to ESMO! Join us on October 22nd at 3:00 PM CET at the Novotel Madrid Campo de las Naciones, Madrid, Spain, for its 2026 edition.
The liquid biopsy movement continues. Building on the conversation started by SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) at ASCO 2026, this forum explores how expanding access to liquid biopsy is now translating into clinical action. Join the pioneers driving this transformation as they share real-world insights from routine practice, demonstrate how decentralized testing is shaping patient care, and reveal how the same model is enabling the next generation of precision oncology biomarkers.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From Access to Action, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don’t miss this unique opportunity and reserve your spot now!
We are delighted to participate in the ESMO AI & Digital Oncology Congress 2026, where you can meet with our Multimodal and BioPharma teams for three exciting days of innovation, networking, and insights into AI-powered solutions and breakthroughs to transform precision oncology.
Join us at booth #11 to:
SOPHiA GENETICS is at the 17th Annual Meeting of the Cancer Genomics Consortium. Find us at Booth #29 to see how the SOPHiA DDM™ Platform is helping laboratories move from fragmented workflows to AI-driven, integrated, end-to-end solutions, able to generate actionable, evidence-based insights at scale.
Discover a platform built for the complexity of cancer genomics, across solid tumors and hematologic malignancies, driven by its global community and trusted by 990+ institutions across 75 countries.
Drop by our booth for an in-depth demo of our end-to-end applications:
Booth #29 hours:
Learn more:
Don't miss: 🎤 Science Café Presentation, Lizmery Ferguson Schires | Royal Sonesta Houston Galleria
Whether you're running a high-volume solid tumor program or building out comprehensive hemato-oncology capabilities, our team can show you how SOPHiA DDM™ streamlines the entire process, from concept to implementation.
Book 15 minutes with our team now or simply stop by our booth. See you in Houston.
Most lab leaders arrive at ADLM with the same question: how do we bring NGS in-house, or scale what we already run, without adding headcount, cost, or turnaround time?
At Booth #1172, the AVITI24 system and the SOPHiA DDM™ Platform’s AI-powered analysis run as one connected workflow. Your lab sequences and interprets its own data, and your data stays in-house.
780+ institutions run SOPHiA DDM™ today
70+ countries, standardizing and scaling NGS workflows
Stop by Booth #1172, wherever your lab is.
Tell us where you are, and we’ll tailor the conversation.
Booth #1172 hours:
Tue Jul 28, 9:30 AM–5:00 PM
Wed Jul 29, 9:30 AM–5:00 PM
Thu Jul 30, 9:30 AM–12:00 PM
See how to stand up sequencing and analysis together, without building a bioinformatics team from scratch.
See where SOPHiA DDM™ removes the bottlenecks you already feel: variant interpretation time, workflow standardization, and QC overhead.
Walk through the cost and turnaround math labs are using to build the business case for in-house testing.
Whether you’re evaluating NGS solutions, expanding your test menu, or exploring how AI can strengthen your genomic pipeline, our teams are ready to talk.
Book 15 minutes with our team now, or simply stop by and say hello. See you in Anaheim.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.